Begin Main Content Area

Announcements

To be added to DDAP's listserv and receive updates from the department, please email RA-DAPressOffice@pa.gov with your name(s), organization, and email address(es). Please include "Listserv" in the subject line.


  
  
Body
10/19/2021 11:48 AMRecovery Rising Update

​In January 2021, the Department of Drug and Alcohol Programs (DDAP) launched a stakeholder-led initiative called Recovery Rising to foster a resilient, diverse, and accessible recovery environment in Pennsylvania. During Phase One of this initiative, from April to July of 2021, Recovery Rising hosted four regional stakeholder meetings with a total of 181 attendees and a Statewide Convening with 128 attendees all representing an extensive range of supports for and pathways to recovery. The discussions were robust, spirited, and passionate.
 
From these convenings, an Advisory Commission of influencers – spanning peer, clinical, family and community roles – prioritized eight key areas on which the commonwealth should focus to embed and expand recovery support services throughout the state. Those broad categories include:

  • Create Equitable, Sustainable, and Flexible Funding for Recovery Supports
  • Build the Capacity and Expand the Role of Recovery Community Organizations
  • Commit to Ensure Diversity, Equity, and Inclusion
  • Make Person-centered and Recovery-oriented Care the Norm
  • Provide the Critical Recovery Support Services Needed in Pennsylvania Improve Access in Rural Areas
  • Provide Education and Training to Reduce Stigma and Equip People to Support All Pathways to Recovery
  • Build the State-level Infrastructure to Support Recovery

Starting this month, DDAP will launch Phase Two. During this phase, the main priorities of the initiative include exploring appropriate ways for building capacity to support recovery work, facilitating dialogue and strategic planning around the best model for a statewide or regional RCOs, and assessing racial equity for recovery support services in PA to determine need and help the state design better policies and issue equity-based funding opportunities. In the near future, DDAP will be once again engaging stakeholders on strategies to realize these goals.  

Learn more about the Recovery Rising initiative by reading the Phase 1 Report. Questions on this work can be directed to ra-darecoveryrising@pa.gov.

10/14/2021 1:37 PMFor Providers: ATLAS Data Collection

​Dear DDAP Stakeholder,

As many of you may know, the Department of Drug and Alcohol Programs (DDAP) will be implementing the ATLAS® (Addiction Treatment Locator, Analysis, and Standards) platform in Pennsylvania over the coming months.

This free multi-state, web-based platform will help ensure that Pennsylvanians and their loved ones struggling with the disease of addiction are able to quickly and easily access treatment resources and information that meets their individual needs. DDAP is excited to partner with Shatterproof, a national non-profit, to collect data from Pennsylvania’s licensed drug and alcohol treatment providers to be included in ATLAS in the Spring of 2022. 


Since Shatterproof publicly launched ATLAS in July 2020, the site has seen over 4,600 unique visitors from Pennsylvania alone. This statistic is extremely important as the pertinent data about Pennsylvania’s licensed treatment providers is not yet available to individuals visiting the website.

DDAP extracted contact information for all licensed drug and alcohol treatment providers from our Survey Agency Information System (SAIS). This information will be used to communicate instructions, including contact verification, from Shatterproof later this month for the completion of the Treatment Data Survey.  The survey collection period is slated to run through January 2022. The average time to complete the survey ranges from 30 minutes to 2.5 hours to complete depending on the number of levels of care available at the facility and whether information was gathered from various individuals in advance. If you do not receive a contact verification email by Tuesday, November 2nd, please contact ATLAS@Shatterproof.org.

To learn more about the data collection process and be a part of the conversation, we encourage you to attend upcoming provider roundtables.

ATLAS Provider Roundtable Webinars

DDAP is not mandating participation in ATLAS.  However, it is strongly encouraged. Your involvement will not only lead to additional outreach for your organization, but more importantly it affords Pennsylvanians in need of drug and alcohol treatment the opportunity to find the care that is most appropriate for their needs. You can find more information on ATLAS, by visiting the website. For all other questions, please contact Kim Coleman, DDAP’s Chief of Staff at kcoleman@pa.gov or Angad Buttar, Shatterproof’s Director of State Engagement at abuttar@shatterproof.org.

We look forward to adding yet another tool in our toolbox for Pennsylvanians looking for the most appropriate drug and alcohol treatment and resources for themselves or a loved one. This can only happen by working with all of you to ensure the success of ATLAS, and most importantly, improving access to high-quality addiction treatment for all Pennsylvanians.

Jennifer S. Smith
Secretary 

10/6/2021 1:26 PMPolicy Bulletin 21-04 - Gambling Manual Modifications

​The Department of Drug and Alcohol Programs (DDAP) released Policy Bulletin 21-04 which documents modifications made to DDAP’s Gambling Treatment Services Manual.

Policy Bulletin 21-04 and the updated manual can be found on the DDAP website.

9/30/2021 1:58 PMUPDATE: Regulatory Suspensions

​The department sent out guidance on June 14, 2021 regarding three temporary regulatory suspensions granted by the Governor’s declaration of a disaster emergency due to the coronavirus pandemic. House Bill 1861, which was signed into law today by Governor Wolf, further extends those regulatory suspensions from September 30, 2021 until March 31, 2022 unless terminated sooner. In addition to the suspensions noted in the department’s previous communication, one additional regulatory suspension from the Department of State, also relevant to the field, is added to the chart below and also suspended until March 31, 2022.

Statute/Regulation​Statute/Regulation PurposeWaiver benefit/explanation
​28 Pa. Code § 715.16(e)​Prohibits narcotic treatment programs (NTPs –methadone clinics) from permitting a patient to receive more than a 2-week take-home supply of medication​In response to COVID-19, SAMHSA is allowing up to 28 days of take-home medications for patients on stable dosages, if the physician deems appropriate.
​28 Pa. Code § 715.9(a)(4)​Requires NTPs to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment.​In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.
​28 Pa. Code § 715.6(d)​Requires NTPs to have narcotic treatment physician services onsite.​In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth
​49 Pa. Code § 16.92(b)(1)
(Department of State)
​Before a patient can be prescribed any controlled substance in Pennsylvania, a person licensed to practice medicine and surgery in the commonwealth, or otherwise licensed or regulated by the State Board of Medicine, must take an initial medical history and conduct an initial physical examination,
unless emergency circumstances justify otherwise.
​In response to COVID-19, the Department of State suspended the initial medical history and physical examination requirement specifically for the treatment of opioid-use disorder with buprenorphine.


If you have any further questions, please contact the Bureau of Program Licensure at (717) 783-8675 or RA-licensuredivision@pa.gov.

9/20/2021 12:18 PMReminder of DDAP Address Change and Licensure Contacts

​The Department of Drug and Alcohol Programs (DDAP) would like to remind the field that we have moved from the Kline Village Shopping Center to One Penn Center.  Please do not send mail or other relevant information to the 132 Kline Village Shopping Center address as we no longer have offices at that address.
 
DDAP’s mailing address:
One Penn Center
2601 N. 3rd Street, 5th Floor
Harrisburg, PA 17110
 
Phone contacts:

  • The telephone number for the Bureau of Program Licensure is: (717) 783-8675.  This number can be used for questions, complaints and requests for additional information.  All calls will be forwarded by a receptionist to the appropriate staff member within DDAP.
  • The fax number for the Bureau of Program Licensure is (717) 265-8308.
  • Any non-licensing telephone calls (i.e., Training, Treatment Manuel, ASAM, Single County Authority) should call (717)783-8200.

 
Resource Accounts:

9/2/2021 1:29 PMSABG Public Comment

​The Department of Drug and Alcohol Programs is providing the opportunity for public comment on the Pennsylvania Substance Abuse Prevention and Treatment Block Grant (SABG) Submission. This submission will occur in three parts: The Substance Abuse Prevention and Treatment Assessment and Plan or Mini-Application which is currently available in draft and available for review; the SAPT Report which will be posted in November, and the Annual Synar Report which will be made available in December.

These documents can be accessed at https://bgas.samhsa.gov utilizing “citizenpa” as your login and “citizen” as your password. Please submit all comments to ra-dagrantsmgmt@pa.gov by Sept. 30.

9/1/2021 11:50 AMNew DDAP Licensing Alert and Information Bulletin

​The Department of Drug and Alcohol Programs (DDAP) released Licensing Alert 02-2021 and Information Bulletin 03-21 regarding Emergency Contact Notification.

Licensing Alert 02-2021
Emergency Contact Notification by Inpatient Drug and Alcohol Treatment Facilities

Information Bulletin 03-21
Emergency Contact Notification by Drug and Alcohol Recovery Houses

8/4/2021 10:50 AMPolicy Bulletin 21-03 - DDAP Manual Modifications

​The Department of Drug and Alcohol Programs (DDAP) released Policy Bulletin 21-03 which documents modifications made to DDAP’s Fiscal Manual and Operations Manual.

Policy Bulletin 21-03 and updated manuals can be found on the DDAP website.

8/2/2021 1:30 PMInformation Bulletin 02-21 - Updated SAMHSA term and condition for marijuana

Information Bulletin 02-21 - This Information Bulletin provides updates on Substance Abuse and Mental Health Services Administration’s (SAMHSA) term and condition for marijuana.

7/29/2021 2:05 PMPolicy Bulletin 21-02 - DDAP Manual Modifications

​The Department of Drug and Alcohol Programs (DDAP) released Policy Bulletin 21-02 which documents modifications made to DDAP’s Prevention Manual, Fiscal Manual, Operations Manual, and Case Management and Clinical Services Manual.

Policy Bulletin 21-02 and updated manuals can be found on the DDAP website.

7/1/2021 3:36 PMReminder: Electronic Reporting System (ERS)

​The Department of Drug and Alcohol Programs (DDAP) would like to remind drug and alcohol treatment facilities of the availability of the Electronic Reporting System (ERS). This new system makes it easier to submit unusual incident reports to DDAP licensing staff for review. Please see this brochure for additional information.

Please note: When logging into the ERS for the first time, you must reset your password. Simply enter your Login ID and click the password reset button. Once you’ve logged into ERS, you will be directed to a Welcome Page with helpful information about how to use ERS.

If you experience technical issues with ERS, please email RA-DAWORKFLOW@pa.gov.

6/29/2021 11:47 AMASAM Alignment – Provider Requests for Extension

​This ASAM Alignment Memorandum establishes a procedure for drug and alcohol treatment providers to request from the Department of Drug and Alcohol Programs additional time beyond July 1, 2021 in reaching substantial alignment with service delivery conditions under The ASAM Criteria, 2013.

Questions regarding this memorandum can be directed to RA-DAASAM@pa.gov.  

6/16/2021 10:58 AMLicensing Alert 01-2021

​Licensing Alert 01-2021 - Use of Medication for Treatment of Substance Use Disorder within Licensed Facilities
This alert provides clarification on the requirements that licensed providers must meet to use certain medications including methadone, buprenorphine, and naltrexone.

Questions on this Licensing Alert can be sent to the Bureau of Program Licensure, Division of Licensing Inspection at (717)783-8675 or RA-licensuredivision@pa.gov.

6/14/2021 4:32 PMUpdate on Regulatory Suspensions

​Good afternoon,

As you may know, the Pennsylvania Department of Drug and Alcohol Program (DDAP) has issued three temporary regulatory suspensions under authority granted by the Governor’s declaration of a disaster emergency due to the coronavirus pandemic. Based on flexibilities granted by SAMHSA, our goal with these suspensions was to respond to the extraordinary circumstances of the last year by allowing entities regulated by DDAP to continue operating throughout the uncertainty of the pandemic.  
On June 10, 2021, the General Assembly passed House Resolution 106 which terminated the Disaster Declaration in whole, effective immediately. However, Governor Wolf signed Act 21 of 2021 on June 11, 2021 to ensure regulatory and statutory suspensions enacted under the Disaster Declaration would continue. Act 21 extends all of the regulatory and statutory suspensions authorized under the Disaster Declaration until September 30, 2021.  More information on Act 21 is outlined in this press release from the Governor.

In the table below you will find the three regulations in which DDAP suspended utilizing the Disaster Declaration. We would like to reiterate that these suspended regulations will continue to be in place until September 30, 2021.

​Statute/Regulation​Statute Regulation Purpose
​Waiver benefit/ explanation
​28 Pa. Code § 715.16(e)​Prohibits narcotic treatment programs (NTPs –methadone clinics) from permitting a patient to receive more than a 2-week take-home supply of medication​In response to COVID-19, SAMHSA is allowing up to 28 days of take-home medications for patients on stable dosages, if the physician deems appropriate.
​28 Pa. Code § 715.9(a)(4)​Requires NTPs to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment.​In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.
​28 Pa. Code § 715.6(d)​Requires NTPs to have narcotic treatment physician services onsite.​In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.


In the coming weeks, we will continue to work with SAMHSA and solicit feedback on the best way to move forward with these suspended regulations to ensure that the drug and alcohol treatment field is able to provide necessary services to patients in the safest, most effective way possible.

Thank you all for your continued work to help better the lives of Pennsylvanians with substance use disorder.

If you have any further questions, please do not hesitate to reach out to the Bureau of Program Licensure, Division of Licensing Inspection at (717) 783-8675 or RA-licensuredivision@pa.gov.


6/2/2021 3:11 PMInformation Bulletin 01-21

Information Bulletin 01-21 - This Information Bulletin provides clarification from the Substance Abuse and Mental Health Services Administration (SAMHSA) on special conditions for federal funding related to medical marijuana.

5/4/2021 1:35 PMHHS Releases New Buprenorphine Practice Guidelines

​HHS Releases New Buprenorphine Practice Guidelines, Expanding Access to Treatment for Opioid Use Disorder

On April 28, 2021, in an effort to get evidenced-based treatment to more Americans with opioid use disorder, the U.S. Department of Health and Human Services (HHS) released new buprenorphine practice guidelines that among other things, remove a longtime requirement tied to training, which some practitioners have cited as a barrier to treating more people.

Signed by HHS Secretary Xavier Becerra, the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder exempt eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives from federal certification requirements related to training, counseling, and other ancillary services that are part of the process for obtaining a waiver to treat up to 30 patients with buprenorphine.

More resources:

5/4/2021 9:10 AMDDAP Training - Treatment Planning with The ASAM Criteria

Treatment Planning with The ASAM Criteria

The Pennsylvania Department of Drug and Alcohol Programs is pleased to announce the availability of a new course on Treatment Planning with The ASAM Criteria. Person centered, action oriented, and strength-based treatment plans rooted in an ASAM multi-dimensional assessment must replace plans based on program participation and prescribed lengths of stay. A quality treatment plan is a collaborative working document between provider and  client. This training will review the tenants of a proper treatment plan, identify common pitfalls, all through case conceptualization.

4/13/2021 1:38 PM2021 PA Psychostimulant Symposium - Call for Presenters

​We are pleased to announce that Pennsylvania Department of Drug and Alcohol Programs, along with our partner the Liberty Mid-Atlantic High Intensity Drug Trafficking Area, will again hold a virtual Psychostimulant Symposium on December 1st and 2nd this year. The data continues to show a need for this interdisciplinary information-sharing and the feedback we received from last year’s event was overwhelmingly positive, a direct result of the many excellent speakers and presenters. It is our hope to meet and exceed the expectations of the attendees and we are asking for your help to do so.  

Dates: December 1-2, 2021 (Wednesday & Thursday).

Format: This is proposed as a one and a half-day virtual event featuring plenary and breakout sessions.

Overview: Both public health and public safety professionals require additional training and information to more readily detect these substances and better respond to psychostimulant overdose victims, and treatment professionals require additional tools to effectively treat patients who misuse psychostimulants. Strategies essential for detecting surges in psychostimulant supply and consumption can aid policymakers and agency leaders in directing resources where most needed.

Target Audience: Law enforcement, criminal justice, health care providers, emergency medical services personnel, drug and alcohol prevention and treatment providers, Single County Authorities (SCAs), government officials, public health professionals, harm-reduction organizations and other interested stakeholders.

Registration: Attendance is free, but pre-registration will be required and limited. More information will be forthcoming.

More Information: Please visit our webpage for information about our 2019 and 2020 PA Psychostimulant Symposium: https://www.ddap.pa.gov/Pages/PA_PS_Symposium.aspx.

Proposals to present at this year’s event can be submitted by emailing ra-daPAPSSymposium@pa.gov on or before June 1, 2021.  Proposals should include:

  • Proposed topic  
  • Relevance of topic
  • Presenter knowledge/credentials
  • Engagement strategies

Any questions can be directed to the resource account ra-daPAPSSymposium@pa.gov.

Psychostimulant Symposium Planning Team
Pennsylvania Department of Drug and Alcohol Programs and
Liberty Mid-Atlantic High Intensity Drug Trafficking Area
https://www.ddap.pa.gov/Pages/PA_PS_Symposium.aspx

4/7/2021 3:42 PMGrant Initiative Funding Opportunity

​The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is pleased to announce a new Grant Initiative Funding Opportunity.

GIFA 21-01 – Recovery Community Support Services
DDAP is accepting applications for Recovery Community Organizations (RCOs) who will expand or enhance recovery support services to individuals in recovery from SUD. Such services include the delivery of recovery coaching through Certified Recovery Specialists (CRS), telephonic supports, the provision of education and employment supports, e.g. job coaching, resume writing, engagement in GED services, additional life-skills support groups and delivery of substance-free social activities, etc. It is the expectation that such RCOs embrace individuals seeking services regardless of their recovery pathway.  Applications are due Monday May 3, 2021 by 12 PM.

3/24/2021 9:10 AMPA Unite Against COVID

​We know there’s a lot of information out there about COVID vaccines, and it can be hard to keep track of it all. That’s why we created the Unite Against COVID Weekly Update. Subscribe to get a round-up of news you can use and answers to your most pressing vaccine questions – delivered directly to your inbox every week. When you have good information, you can make good decisions.

The rollout of COVID-19 vaccine gives us hope, and a path back to our lives. Learn more at pa.gov/covid.

3/19/2021 8:02 AMDeadline Extension - MDAIR Member Application Survey

DDAP Seeking MDAIR Team Members
The Department of Drug and Alcohol Programs (DDAP) is seeking members for the Medication Death and Incident Review (MDAIR) Team. This team will review circumstances surrounding medication-related deaths and incidents for medications approved by the FDA for the treatment of opioid use disorder. These reviews will lead to recommendations that promote safety, reduce deaths and incidents, as well as improve treatment.  

DDAP is excited about the overwhelming amount of interest so far. If you’re interested in applying, we have received a limited number of applications from the fields in red:

  • narcotic treatment programs
  • licensed drug and alcohol treatment providers
  • law enforcement
  • the medical community
  • district attorneys
  • coroners and medical examiners
  • community members
  • individuals with a substance use disorder or family advocates
  • individuals from recovery organizations
  • individuals that prescribe buprenorphine with a DEA number related to prescribing
  • toxicologists

The deadline to apply has been extended to March 26, 2021. DDAP will continue to welcome applications from all of the above categories until that time. If you are interested in sharing your knowledge, positively affecting the drug and alcohol treatment system, and can dedicate approximately 30 hours per year, please complete the application via SurveyMonkey. Please pass this message along to other individuals who may be interested in applying.

DDAP will review applications and select members within 3 weeks of the application closing date. Questions can be submitted to Derrick Pelletier at dpelletier@pa.gov.

3/8/2021 9:26 AMDDAP Seeking Medication Death and Incident Review Team Members

The Department of Drug and Alcohol Programs (DDAP) is seeking members for the Medication Death and Incident Review (MDAIR) Team. This team will review circumstances surrounding medication-related deaths and incidents for medications approved by the FDA for the treatment of opioid use disorder. These reviews will lead to recommendations that promote safety, reduce deaths and incidents, as well as improve treatment. The MDAIR Team is established by Act 126 of 2020.

DDAP is seeking representation from:

  • narcotic treatment programs
  • licensed drug and alcohol treatment providers
  • law enforcement
  • the medical community
  • district attorneys
  • coroners and medical examiners
  • community members
  • individuals with a substance use disorder or family advocates
  • individuals from recovery organizations
  • individuals that prescribe buprenorphine with a DEA number related to prescribing
  • toxicologists

If you are interested in sharing your knowledge, positively affecting the drug and alcohol treatment system, and can dedicate approximately 30 hours per year, please complete the application via SurveyMonkey by March 19, 2021.
 
DDAP will review applications and select members within 3 weeks of the application closing date. Questions can be submitted to Derrick Pelletier at dpelletier@pa.gov.​

3/4/2021 3:31 PMProblem Gambling Awareness Month Kickoff

​The 2021 Problem Gambling Awareness Month Kickoff recording is now available.
Watch: https://ddap.webex.com/ddap/ldr.php?RCID=fe818e74df2e4ce587d93cef47cc94db
Password: 8xJTCw3p

2/25/2021 10:52 AMDDAP Prevention Manual Modifications

​The Department of Drug and Alcohol Programs has released Policy Bulletin 21-01 which documents modifications made to the DDAP Prevention Manual relating to DDAP-funded paid advertisements.

Policy Bulletin 21-01 and the updated 2020-2025 Prevention Manual can be found on the DDAP website.


2/19/2021 1:52 PMFebruary COVID-19 Update

Rite Aid Pharmacy Partnership with Residential Drug and Alcohol Treatment Providers
The Pennsylvania Departments of Human Services, Health, and Drug and Alcohol Programs have established a partnership with Rite Aid to ensure providers of congregate care settings throughout the commonwealth have access to the COVID-19 vaccine. The partnership is a result of a survey sent to DDAP residential treatment providers on January 26, 2021, to better understand how many providers were still in need of establishing a partnership with a vaccine provider in Pennsylvania.
 
If you are a residential treatment provider still in need of establishing a partnership, please let us know by contacting DDAP’s Dan Miller at ddap-eplo@pa.gov.  If your facility meets the qualifications to participate in this partnership, we will connect you with a Rite Aid location who can come to your residential facility to vaccinate your residents and staff. To identify a vaccine provider in your local area, visit https://www.health.pa.gov/topics/disease/coronavirus/Vaccine/Pages/Vaccine.aspx.

Your Turn Eligibility Tool
If you or your staff are unsure if you qualify to receive a COVID-19 vaccine during phase 1a of Pennsylvania’s vaccine distribution plan, the Wolf Administration’s recently released the Your Turn tool to identify eligibility and provide notifications when you, or a loved one, are eligible for vaccinations. To access the tool, visit https://covidportal.health.pa.gov/s/Your-Turn.
 
Vaccine Supply Remains Limited
It is important to note that the vaccine supply is still very limited throughout the commonwealth and we ask for your patience as more vaccine becomes available. For the most up to date information on the COVID-19 vaccine and Pennsylvania’s vaccine distribution plan, visit the Department of Health’s website www.health.pa.gov.

2/8/2021 2:35 PMSAMHSA’s New Series of Advisories on Substance Use Disorder Treatment

SAMHSA has published a series of Advisories based on existing Treatment Improvement Protocols (TIPs) and Technical Assistance Publications (TAPs). These Advisories summarize updated guidance and recommendations on topics in the substance use disorder (SUD) treatment field. The new Advisories are listed below and links to each can be found here.

Advisory: Comprehensive Case Management for Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 27, Comprehensive Case Management for Substance Abuse Treatment. It surveys the underlying principles and models of case management, discusses reasons SUD treatment providers might consider implementing or expanding the use of case management, and lists some case management resources and tools.

Advisory: Using Motivational Interviewing in Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in SUD treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

Advisory: Screening and Treatment of Viral Hepatitis in People With Substance Use Disorders
Published: January 2021
This Advisory is based on TIP 53, Addressing Viral Hepatitis in People With Substance Use Disorders. It offers guidance to providers and administrators in SUD treatment programs on screening for, and treating clients with, hepatitis A, hepatitis B, and hepatitis C infections.

Advisory: Screening and Treatment of Substance Use Disorders Among Adolescents
Published: January 2021
This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders and TIP 32, Treatment of Adolescents With Substance Use Disorders. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

Advisory: Addressing Suicidal Thoughts and Behaviors in Substance Use Treatment
Published: January 2021
This Advisory is based on TIP 50, Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment. It provides strategies for identifying and addressing suicidal thoughts and behaviors among individuals with SUDs.

Advisory: Treating Substance Use Disorders Among People With HIV
Published: January 2021
This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for SUD treatment providers to effectively engage people with HIV in SUD treatment.

Advisory: Group Therapy in Substance Use Treatment
Published: January 2021
Based on TIP 41, Substance Abuse Treatment: Group Therapy, this Advisory provides an overview of goals, processes, group-specific approaches, resources, and common elements that support favorable outcomes in group therapy.

Advisory: Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder
Published: January 2021
This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for alcohol use disorder (AUD), and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

Advisory: The Importance of Family Therapy in Substance Use Disorder Treatment
Published: January 2021
This Advisory is based on TIP 39, Substance Use Disorder Treatment and Family Therapy. It surveys basic factors for programs and providers to consider when implementing family-related therapy approaches, goals and processes for conducting effective family counseling, and resources for further learning about family therapy techniques and models.

Advisory: The Substance Use Disorder Counseling Competency Framework: An Overview
Published: January 2021
This Advisory is based on TAP 21, Addiction Counseling Competencies: The Knowledge, Skills, and Attitudes of Professional Practice. It discusses the development of the counseling competencies and the validated research on which they are based, provides a simplified overview of their structure and the elements of a typical competency, and outlines how these competencies are changing the field of SUD treatment nationwide. The Advisory also addresses the critical role of cultural competence.

Advisory: Integrating Vocational Services into Substance Use Disorder Treatment
Published: January 2021
This Advisory, based on TIP 38, Integrating Substance Abuse Treatment and Vocational Services, presents strategies and resources for SUD treatment counselors and program directors to improve outcomes for clients in recovery by helping them find and keep employment and deal with workplace stresses. This Advisory is directed to programs serving clients who are unemployed, underemployed, or struggling in workplace settings.

1/25/2021 11:02 AMFree home HIV test kits

​The Pennsylvania Department of Health, in partnership with the Pennsylvania Expanded HIV Testing Initiative (PEHTI) and the HIV Prevention and Care Project (HPCP), has introduced HIV Self-Testing (HST) for individuals who reside in Pennsylvania (excluding Philadelphia County). The goal of the getmyHIVtest.com program is to help people get tested who wouldn’t otherwise go to their doctor or to a testing clinic.  

Tests are available from the website getmyhivtest.com. Individuals are asked to read the information on the website and answer a few questions in order to receive an FDA-approved, OraQuick home HIV test kit mailed to the address they provide. Support for clients who request and administer the HIV self-test is available through OraQuick and the HPCP, as noted on the website.   

Individuals who reside in Philadelphia County should visit PhillyKeepOnLoving.com to order the HIV Self-test kit and for additional information about testing from the Philadelphia Department of Public Health.   

If you have any questions, please send an email to info@getmyHIVtest.com.

1/14/2021 9:48 AMJanuary COVID-19 Vaccine Update

​Hello DDAP Stakeholders,

I hope you are well, safe, and healthy as we start the new year.

I would like to share updates on the commonwealth’s COVID-19 vaccination process, as well as provide tips on how you can prepare your organizations to receive vaccine.

Vaccination Process
Last Friday, the Department of Health (DOH) released the fourth version of its COVID-19 Interim Vaccination Plan. The plan is both fluid and flexible to meet the latest federal guidance and recommendations. It will continue to receive updates. DOH released this version with a Feedback Form that invites public comment on the plan. This feedback will help inform Pennsylvania’s  vaccination planning.

Pennsylvania continues to work its way through the initial phase of vaccine distribution – Phase 1A. This phase is focused on frontline, healthcare personnel, emergency medical first responders, and long-term care facility residents. The time it will take to complete this phase is influenced by factors like:

  • the limited amount of available vaccine,
  • which vaccines are available,
  • the storage capabilities of private/public partners, and
  • Pennsylvania’s allocation from the federal government.

Many of DDAP’s stakeholders will be in the next phase of vaccinations, Phase 1B. While the above factors make it difficult to determine when or where that phase will start, there are several things you can do to prepare your organizations.

How to Prepare
Identify one nearby hospital or healthcare system enrolled to provide COVID-19 vaccine.

  • Monday, the Department of Health launched its Pennsylvania Vaccine Provider Map. This map shows all entities that are enrolled to provide vaccine. Using this map, you should identify a nearby location where your staff can get vaccine at the appropriate time.
  • The Map identifies contact information for the specific location’s vaccine liaison. Connect with the individual to ensure you have all necessary information to prepare your staff.

Prioritize Staff

  • Due to vaccine availability, your entire staff might not be able to receive vaccine at the same time. Be prepared to prioritize those staff that are at greatest risk for exposure.
  • Encourage staff to visit their primary care physicians to review their medical history, ensuring they are eligible for vaccination.

Prepare Necessary Documentation for Staff

  • Staff will have to provide proof of occupation to receive vaccine. This could include a state license or certification, letter from employer on organization letterhead, facility identification/security badge or other proof of occupation. Ensure that these documents are ready.

Stay Informed

  • For the most up-to-date information on Pennsylvania’s vaccine distribution, I encourage each of you to regularly visit the Department of Health’s COVID-19 vaccine portion of their website, as well as their news section which provides updates to how much vaccine and where vaccine was received in Pennsylvania.  Feel free to utilize the COVID-19 vaccine toolkit which provides vaccine development background, facts, and graphics for your facilities and social media channels.

DDAP’s Commitment
DDAP’s commitment to each of you is to be transparent throughout the vaccine planning process. We are working closely with the Department of Health to provide information to you as quickly as possible, but I ask for your continued patience as the logistics are developed and finalized.

Thank you for your continued patience as more information becomes available and for your continued partnership in ensuring all members of Pennsylvania’s drug and alcohol system remains safe.

Questions can be forwarded to Derrick Pelletier at dpelletier@pa.gov.

Be well,
Jen Smith
DDAP Secretary

1/7/2021 9:29 AMUpdated ASAM document available

​DDAP has replaced the Addendum PA-Specific Alignment Requirements 2.0 (IOP/PHP) document that was previously posted to our website. The revised document specifically focuses on items related to Partial Hospitalization Program requirements that had not been fully identified in the prior edition.

12/22/2020 9:31 AMMessage from Secretary Smith

​Thank you for your continued dedication to the health and safety of Pennsylvanians, we could not do what we do without you. Happy holidays from all of us at DDAP.

WATCH VIDEO

Screenshot_2020-12-16 SecretaryMessage4 mp4.jpg

1 - 30Next